Treatment of generalized granuloma annulare with tildrakizumab

Australas J Dermatol. 2022 Aug;63(3):e285-e288. doi: 10.1111/ajd.13858. Epub 2022 May 2.

Authors

Andrew Awad¹, Alexander Nirenberg², Rodney Sinclair^{1

3

4}

Affiliations

¹ Sinclair Dermatology, East Melbourne, Victoria, Australia.
² Dorevitch Pathology, Heidelberg, Victoria, Australia.
³ University of Melbourne, Parkville, Victoria, Australia.
⁴ Epworth Healthcare, Richmond, Victoria, Australia.

PMID: 35500134
DOI: 10.1111/ajd.13858

No abstract available

Keywords: granuloma annulare; granulomatous; necrobiotic; tildrakizumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Granuloma Annulare* / complications
Granuloma Annulare* / drug therapy
Humans
Skin

Substances

Antibodies, Monoclonal, Humanized
tildrakizumab